Clinical approval of elinzanetant reveals effective management of menopausal symptoms, suggesting a new treatment option.
The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.
No takes yet. Share an insight, caveat, or question.
Rowe et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: